US and European Computer Aided Detection (CAD) Industry

  • May 2013
  • -
  • Global Industry Analysts
  • -
  • 102 pages

This report analyzes the US and European markets for Computer Aided Detection (CAD) in US$ Million and Number of Units. The report analyzes the US market in Value and Volume terms by the following Application Segments - Breast, and Chest. The European market is analyzed in Value terms by the following Application Segments - Breast, Chest, and Colon. Annual estimates and forecasts are provided for the period 2011 through 2018. The report profiles 28 companies including many key and niche players such as EDDA Technology, Inc., Hologic, Inc., iCAD, Inc., Invivo Corporation, Medipattern Corp., Merge Healthcare Incorporated, Riverain Technologies, Siemens Healthcare, and VuCOMP Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. A US AND EUROPEAN MARKET REPORT

1. OUTLOOK II-1
Computer Aided Detection - Offering “Second Look” for
Radiology Analysis II-1
The Need for Early Diagnosis and Role of CAD II-1
Market Highlights II-2
Major Drivers and Restraints II-2
Breast CAD to Hold its Fort in the CAD Market II-3
Economy Slowdown Drubs Market Growth II-3

2. MARKET OVERVIEW and TRENDS II-5
From “Second Reader” to “First Reader” Use - the Unconquered
Avenue of CAD Systems II-5
CAD Use Rises despite Controversies II-5
Replacements to Fuel Market Growth II-6
High Dependence on Related Modality Continues II-6
Market Calls for Higher Efficiencies in CAD II-6
Product Developments Underway to Expand Utility II-6
Information Provision - A Key Feature under Development for
Enhanced Efficiency II-7
Research finds Interactive Use of CAD More Efficient II-8
Rising Incidence of Cancer - A Major Market Driver II-8
Cancer Prone Sites based on Age II-8
World Cancer Statistics - Incidence and Mortality Data II-9
Table 1: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported in
Thousands for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-9

Table 2: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths in Thousands
for Asia-Oceania, Europe, North America, Latin America and the
Caribbean, and Africa (includes corresponding Graph/Chart) II-10

Table 3: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung and
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-10

Table 4: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung and Bronchus and Liver Cancers (includes
corresponding Graph/Chart) II-11

Table 5: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung and Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-11

Table 6: Global Cancer Mortality in Women for Select Cancers
(2012): Number of Deaths in Thousands for Breast, Lung and
Bronchus, Colorectal and Liver (includes corresponding
Graph/Chart) II-11

Table 7: World Breast Cancer Statistics: Top 20 Countries
with Highest Breast Cancer Rates (includes corresponding
Graph/Chart) II-12

3. APPLICATION LANDSCAPE II-13
Present Applications of CAD II-13
What Lies Ahead at the Application Front? II-13
CAD in Breast Cancer II-13
CAD Simplifies Breast MRI Image Analysis; Tremendous Scope
for Adoption Ahead II-13
Breast MRI - Lagging behind Mammography in Cancer Detection II-14
CAD Solutions for Breast Cancer II-14
SecondLook Digital CAD (iCAD) II-14
R2 ImageChecker (Hologic, Inc.) II-14
SpectraLook CAD Solution (iCAD) II-14
DynaCAD Breast (Invivo) II-15
CADstream Breast MRI Application (Merge Healthcare) II-15
List of Approved CAD Solutions for Breast MRI II-15
CAD in Prostate Cancer II-16
CAD in Lung Cancer II-16
The Background II-16
An Overview of CAD Solutions for Lung Cancer Detection II-17
IQQA (EDDA Technology) II-17
OnGuard (Riverain Medical) II-17
xLNA (Philips) II-18
syngo CAD Solutions (Siemens) II-18
CAD in Liver Cancer II-18
CAD Solutions for Liver Cancer Detection II-18
CADstream (Merge Healthcare) II-18
IQQA (EDDA Technology) II-18
CAD in the Detection of Prostate Cancer II-19
Available CAD Solutions for Prostate Cancer II-19
CAD in the Detection of Colon Cancer II-19
CAD in Cardiology II-20
Increasing Need for CAD in Cardiology II-20
Automatic Workflow Integration Fuels Demand for Cardiac CAD II-20
Significant Hurdles Exist for CAD in Cardiology II-21

4. COMPETITION II-22
Competitive Landscape II-22
iCAD - A Leading Independent Player in the Mammography CAD
Segment II-22
Restructuring Likely in CAD Industry II-22

5. REGIONAL PERSPECTIVE II-24

5a. THE UNITED STATES II-24
A.Market Analysis II-24
Current and Future Analysis II-24
CAD to Gain from Rapid Growth in CTC Volumes II-24
FDA Approved CAD Software: 1998-2012 II-25
Challenges in Evaluation Dents Approvals of New CAD Systems II-27
Final Guidance Documents on CAD offers Respite to Industry
Players II-27
CAD Devices, as Defined by the FDA II-28
Guidance on 510(k) Application II-28
FDA’s FFDM Reclassification to Benefit CAD Market II-28
Physicians’ Reluctance to Follow USPSTF - A Shot in the Arm
for CAD Manufacturers II-28
Mammography and Breast MRI, and CAD Reimbursement in the US II-29
CMS Coverage for Screening and Diagnostic Mammography and
Breast MRI - A Review II-29
Table 8: Medicare Reimbursement Codes and Allowable Rates
for CAD in Mammography: 2011-2013 II-30
Low and Spotty Reimbursement Mars CAD in Prostate Cancer
Detection II-30
No Separate Codes for CAD in Prostate MRI II-30
Cancer Statistics II-31
Rising Incidence of Cancer II-31
Table 9: Cancer Incidence in the US by Site for Male and
Female Populations (2013): Breakdown of Number of New
Cases for Breast, Lung and Bronchus, Colon, Liver and
Intrahepatic Bile Duct, Prostate and Other Cancers
(includes corresponding Graph/Chart) II-31

Table 10: Cancer Mortality in the US by Site for Male and
Female Populations (2013): Breakdown of Number of Deaths
for Breast, Lung and Bronchus, Colon and Rectum, Liver and
Intrahepatic Bile Duct, Prostate and Other Cancers
(includes corresponding Graph/Chart) II-32
B.Market Analytics II-33
Table 11: US Recent Past, Current and Future Analysis for
Computer Aided Detection (CAD) by Application - Breast,
Chest and Other CAD Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2018 (includes corresponding Graph/Chart) II-33

Table 12: US Historic Review for Computer Aided Detection
(CAD) by Application - Breast, Chest and Other CAD Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2010 (includes corresponding
Graph/Chart) II-34

Table 13: US 12-Year Perspective for Computer Aided
Detection (CAD) by Application - Percentage Breakdown of
Dollar Sales for Breast, Chest and Other CAD Markets for
Years 2007, 2012 and 2018 (includes corresponding
Graph/Chart) II-35

5b. EUROPE II-36
A.Market Analysis II-36
Current and Future Analysis II-36
CAD Market in Europe - An Overview II-36
Economic Woes Dampen European CAD Market Prospects II-36
Long-Term Prospects Appear Brighter II-37
Rising Incidence of Cancer II-37
Table 14: European Cancer Incidence by Geographic Region
(2012): Number of New Cancer Cases Reported in Thousands
for Western Europe, Northern Europe, Southern Europe, and
Central and Eastern Europe (includes corresponding
Graph/Chart) II-38

Table 15: Cancer Incidence in Western Europe by Site
(2012): Number of New Cancer Cases Reported in Thousands
for Prostate, Breast, Colorectal, Lung and Other Cancers
(includes corresponding Graph/Chart) II-38

Table 16: Cancer Incidence in Northern Europe by Site
(2012): Number of New Cancer Cases Reported in Thousands
for Breast, Prostate, Colorectal, Lung and Other Cancers
(includes corresponding Graph/Chart) II-39

Table 17: Cancer Incidence in Southern Europe by Site
(2012): Number of New Cancer Cases Reported in Thousands
for Colorectal, Breast, Lung, Prostate and Other Cancers
(includes corresponding Graph/Chart) II-39

Table 18: Cancer Incidence in Central and Eastern Europe by
Site (2012): Number of New Cancer Cases Reported in
Thousands for Lung, Colorectal, Breast, Stomach and Other
Cancers (includes corresponding Graph/Chart) II-39
B.Market Analytics II-40
Table 19: European Recent Past, Current and Future Analysis
for Computer Aided Detection (CAD) by Application - Breast,
Chest and Other CAD Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2018 (includes corresponding Graph/Chart) II-40

Table 20: European Historic Review for Computer Aided
Detection (CAD) by Application - Breast, Chest and Other CAD
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2010 (includes
corresponding Graph/Chart) II-41

Table 21: European 12-Year Perspective for Computer Aided
Detection (CAD) by Application Segment - Percentage
Breakdown of Breast, Chest and Other CAD Markets for Years
2007, 2012 and 2018 (includes corresponding Graph/Chart) II-42

6. PRODUCT OVERVIEW II-43
CAD - An Introduction II-43
A Brief History of CAD II-43
Methodology II-43
Sensitivity / Specificity II-44
Absolute Detection Rate II-44
Applications of Computer-Aided Detection II-44
Breast Cancer: II-44
Lung Cancer (Bronchial Carcinoma): II-44
Evolution of Computer-Aided Detection for Mammography II-44
CAD Technology - Working Operation II-45
Existing Limitations of CAD II-45

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-46
iCAD Obtains FDA Clearance for Mammography CAD Platform II-46
VuCOMP Receives Premarket Approval from FDA for M-Vu Digital
Mammography CAD II-46
VuCOMP Receives Premarket Approval from FDA for M-Vu Film
Mammography CAD II-46
iCAD Introduces Advanced Mammography CAD System II-46
Parascript Unveils Updated AccuDetect CAD Technology II-47
Parascript Unveils AccuDetect 5.0 Software II-47
Confirma® Rolls Out CADstream Prostate Application II-48
iCAD Rolls Out SecondLook® Premier CAD Technology II-48
iCAD Launches VeraLook CTC CAD Solution with Products of Vital
Image II-48
Medicsight Obtains FDA 510(k) Approval to Market ColonCAD System II-49
iCAD Obtains SFDA Approval in China for SecondLook® Digital
CAD Technology II-49
iCAD Introduces New VeraLook CAD Technology Version for CT
Colonography in Europe II-49
Medicsight Launches MedicRead 3.0 Colon II-50
Confirma Introduces New Applications for MRI-CAD II-50
Medicsight Introduces ColonCAD API 4.0 II-50
iCAD Expands SecondLook Digital CAD Technology Market II-50
Definiens Launches LymphExpert II-51
iCAD to Launch New CAD Solutions II-51
Parascript Introduces AccuDetect 2.0 II-51
MeVis Unveils MeVis Visiaâ„¢ CT Lung System II-51
Medipattern Introduces New B-CAD Versions II-52
Fujifilm Unveils FCR Digital Mammography CAD MV-SR657 II-52
iCAD Introduces SecondLook Digital for Sectra's MicroDose
Mammography System II-52
iCAD Launches TotalLook MammoAdvantage System II-52

8. RECENT INDUSTRY ACTIVITY II-53
Real Time Tomography Inks Licensing Agreement with im3D II-53
iCAD and Invivo Ink Agreement II-53
Planmed and Three Palm Software Ink Partnership Agreement II-53
Sectra Signs Agreement with Merge Healthcare II-54
Medipattern Inks Agreement with TomTec Imaging Systems II-54
INFINITT North America and Medicsight Enter into Marketing
Partnership II-54
iCAD and Carestream Sign Global Distribution Agreement II-55
Medicsight Signs Agreement with Ziosoft II-55
Canon and MEDIAN Technologies Ink Agreement II-56
iCAD Enters into Partnership with Mtakina International II-56
Merge Healthcare Acquires Confirma II-57
Merge Healthcare Expands EU Distribution Agreement with MEDRAD II-57
Alma IT Systems and Medicsight Ink Agreement II-57
Medipattern and LIRA Enter into B-CAD-FOR-LIFEâ„¢ Agreement II-57
Definiens and Imaging Service Enter into Partnership II-58
iCAD Purchases CAD Sciences Assets II-58
Medicsight and INFINITT Enter Into Partnership II-58
iCAD® Receives Approval from FDA II-59
Medipattern and iPACS Ink Agreement II-59
Riverain Bags Veterans Affairs CAD Contract II-59

9. FOCUS ON SELECT PLAYERS II-60
EDDA Technology, Inc. (US) II-60
Hologic, Inc. (US) II-60
iCAD, Inc. (US) II-61
Invivo Corporation (US) II-63
Medipattern Corp. (Canada) II-63
Merge Healthcare Incorporated (US) II-64
Riverain Technologies (US) II-65
Siemens Healthcare (Germany) II-65
VuCOMP Inc. (US) II-66


III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 28 (including Divisions/Subsidiaries - 30)

The United States (17)
Canada (1)
Japan (1)
Europe (10)
- Germany (3)
- The United Kingdom (1)
- Spain (1)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (1)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.